Financial Results Announcement - ImmuCell Corporation announced preliminary, unaudited product sales for the year ended December 31, 2024[6]. - The press release detailing the financial results was issued on January 9, 2025[6]. - The report does not include specific financial figures or performance metrics in the provided content[6]. - The financial statements and exhibits related to the report are included as an attachment[8]. Company Information - The company is listed on The NASDAQ Capital Market under the trading symbol ICCC[4]. - The company has not indicated whether it is an emerging growth company[5]. - The report was signed by Michael F. Brigham, the President and CEO of ImmuCell Corporation[12]. Product and Market Development - No new product or technology developments were mentioned in the available content[6]. - There are no details regarding market expansion or acquisitions in the provided information[6]. Regulatory Compliance - The filing is intended to satisfy the requirements of the Securities Exchange Act of 1934[7].

Core Viewpoint - ImmuCell Corporation reported significant growth in product sales and improved financial performance for the year ended December 31, 2024, indicating a recovery from previous contamination issues and a focus on enhancing production yields and gross margins [2][5][6]. Financial Performance - Product sales for Q4 2024 increased by 52% to approximately $7.8 million compared to $5.1 million in Q4 2023 [5][6]. - For the full year 2024, product sales also rose by 52% to approximately $26.5 million, up from $17.5 million in 2023 [5][6]. - Gross margin improved to 37% in Q4 2024 from 25% in Q4 2023, and for the full year, it increased to 30% from 22% [6]. - Net income for Q4 2024 was $515,000, or $0.06 per diluted share, compared to a net loss of $1,140,000, or ($0.15) per share in Q4 2023 [6][11]. - The company achieved positive EBITDA of approximately $1,331,000 in Q4 2024, contrasting with negative EBITDA of approximately ($311,000) in Q4 2023 [6][15]. Balance Sheet Highlights - Cash and cash equivalents rose to $3.8 million as of December 31, 2024, from $979,000 a year earlier [10][13]. - Net working capital increased to approximately $10.6 million from $7.3 million [10][13]. - Stockholders' equity grew to $27.5 million from $25 million [10][13]. Product Development and Regulatory Updates - The company is working towards FDA approval for Re-Tain, with a Controlled Launch pending FDA clearance of inspectional observations [2][6]. - Discussions with the FDA are ongoing to expedite the review process for the product [2]. Company Overview - ImmuCell Corporation focuses on developing and marketing products that enhance the health and productivity of dairy and beef cattle, including its First Defense product line and the upcoming Re-Tain treatment [17].

Company Overview - ImmuCell Corporation is an animal health company focused on developing, manufacturing, and marketing products that enhance the health and productivity of dairy and beef cattle [5] - The company is known for its product First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a treatment for subclinical mastitis in dairy cows [5] Financial Reporting - ImmuCell expects to report unaudited financial results for the quarter and year ended December 31, 2024, after the market closes on February 25, 2025 [1] - The company anticipates no change to the preliminary sales results for the fourth quarter and year ended December 31, 2024, which were disclosed on January 9, 2025 [3] - An Annual Report on Form 10-K is expected to be filed on or before March 31, 2025 [3] Conference Call - A conference call to review the unaudited financial results is scheduled for February 26, 2025, at 9:00 AM ET [2] - Interested parties can access the call via specific toll-free and international numbers, with a replay available until March 5, 2025 [2] Investor Relations - Investors are encouraged to review the updated Corporate Presentation slide deck available on the company's website, which provides an overview of the business [4] - An updated version of the slide deck will be made available after the market closes on February 25, 2025 [4]

Core Points - ImmuCell Corporation is set to report unaudited financial results for the quarter and year ended December 31, 2024, after market close on February 25, 2025 [1] - A conference call to discuss these results is scheduled for February 26, 2025, at 9:00 AM ET [2] - The company anticipates no changes to the preliminary sales results disclosed on January 9, 2025 [3] - An updated Corporate Presentation slide deck will be available after market close on February 25, 2025, providing an overview of the company's business [4] - ImmuCell focuses on developing products that enhance the health and productivity of dairy and beef cattle, including First Defense and the novel treatment Re-Tain [5]

PORTLAND, Maine, Jan. 16, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has settled an insurance claim covering some of the losses incurred from production contamination events. The Company settled a long outstanding insurance claim related to previously dis ...

PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2024. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaud ...

PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2024. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaud ...

Zacks Investment Research has recently initiated the coverage of ImmuCell Corporation (ICCC) with a “Neutral” recommendation. The Portland, ME-based company, founded in 1982, specializes in scientifically proven animal health products aimed at improving the health and productivity of dairy and beef cattle. This balanced outlook reflects the company's potential and the risks inherent in its operations and market environment.ImmuCell's market-leading First Defense product line stands out in the $75-million sc ...

Shares of ImmuCell Corporation (ICCC) have lost 3% since the company reported earnings for the third quarter of 2024. Notably, the S&P 500 index declined 2% in the same period. Over the past month, ICCC stock has seen a 0.3% decline against the S&P 500's 0.7% rise, highlighting relatively underwhelming performance amid broader market strength.Q3 Sales & Earnings PerformanceThe company reported third-quarter 2024 earnings per diluted share of 9 cents, down from 12 cents in the prior-year quarter.ImmuCell's p ...

ImmuCell Corporation (NASDAQ:ICCC) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Joe Diaz - Lytham Partners Michael Brigham - President and CEO Conference Call Participants George Melas - MKH Management Operator Good morning and welcome to ImmuCell Corporation Reports Third Quarter September 30, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please ...